Our data suggest that Gpr35 deficiency exacerbates PD-related motor deficits, neuroinflammation, and dopaminergic neuron loss, while activation of Gpr35 by its agonist KYNA exerts neuroprotective and anti-inflammatory effects. Here, GPR35 is linked to Parkinson disease.